Please check your internet connection and try again.
# Phenobarbitone for Gilbert Syndrome
## Overview
- **Classification**: Barbiturate, Anticonvulsant, Sedative-Hypnotic.
- **Mechanism**: Potentiates GABA-A receptor activity, depressing CNS. Induces hepatic microsomal enzymes, including UGT1A1 (UDP-glucuronosyltransferase), which glucuronidates bilirubin.
## Primary Indications
1. **Epilepsy** - Management of generalized tonic-clonic and partial seizures.
2. **Sedation** - Short-term treatment of insomnia and pre-operative sedation.
3. **Hyperbilirubinemia** - Reduction of unconjugated bilirubin, e.g., in neonatal jaundice or **Gilbert Syndrome**.
## Adult Dosing
### Standard Dosing
**Gilbert Syndrome / Enzyme Induction**
- **Dose**: **30 mg** to **60 mg**
- **Frequency**: Once daily, usually at bedtime
- **Route**: Oral
- **Duration**: Chronic, based on bilirubin levels and tolerance
### Dose Adjustments
- **Renal Impairment**: Caution. Reduce dose by **25-50%** in severe renal failure (CrCl < 10 mL/min).
- **Hepatic Impairment**: Contraindicated in severe liver disease. Use with extreme caution and reduced doses in mild-moderate impairment.
- **Elderly Patients**: Start at lower end of dosing range due to increased sensitivity and decreased metabolism/excretion.
## Pediatric Dosing
### Neonates (0-28 days)
**Neonatal Hyperbilirubinemia / Enzyme Induction**
- **Dose**: **2.5 mg/kg** to **5 mg/kg**
- **Frequency**: Once daily or divided twice daily
- **Maximum**: Not well-established for this indication; monitor for sedation.
- **Special Notes**: Used cautiously, often in cases of severe or persistent unconjugated hyperbilirubinemia not responding to phototherapy.
### Infants (1-12 months)
**Gilbert Syndrome / Enzyme Induction**
- **Dose**: **1 mg/kg** to **3 mg/kg**
- **Frequency**: Once daily, usually at bedtime
- **Maximum**: **60 mg/day** (or adult max for enzyme induction).
- **Special Notes**: Liquid formulations are available for accurate dosing.
### Children (1-12 years)
**Gilbert Syndrome / Enzyme Induction**
- **Dose**: **1 mg/kg** to **3 mg/kg**
- **Frequency**: Once daily, usually at bedtime
- **Maximum**: **60 mg/day**.
- **Special Notes**: Monitor for sedation and behavioral changes.
### Adolescents (13-18 years)
**Gilbert Syndrome / Enzyme Induction**
- **Dose**: Typically adult doses: **30 mg** to **60 mg**
- **Frequency**: Once daily
- **Maximum**: **60 mg/day** for enzyme induction.
## Safety Information
### Contraindications
- **Absolute**: Acute intermittent porphyria
- **Absolute**: Severe respiratory depression
- **Absolute**: Severe hepatic or renal impairment
- **Absolute**: Hypersensitivity to barbiturates
- **Relative**: History of drug dependence
### Common Adverse Effects
- **Very Common (>10%)**: Sedation, drowsiness, lethargy
- **Common (1-10%)**: Ataxia, dizziness, nystagmus, cognitive impairment, paradoxical excitation (in children/elderly)
- **Serious but Rare**: Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), respiratory depression, megaloblastic anemia, hepatitis, dependence.
### Key Drug Interactions
- **CNS Depressants (e.g., Alcohol, Opioids, Benzodiazepines)**: Increased sedation, respiratory depression. Avoid concurrent use.
- **Oral Contraceptives**: Reduced efficacy due to enzyme induction (CYP3A4). Advise alternative contraception.
- **Warfarin**: Decreased anticoagulant effect due to enzyme induction. Monitor INR closely, adjust warfarin dose.
- **Corticosteroids**: Reduced efficacy due to enzyme induction. Dose adjustment may be needed.
- **Valproic Acid**: Inhibits phenobarbitone metabolism, increasing levels. Monitor phenobarbitone levels.
## Monitoring & Follow-up
- **Before Treatment**: Liver function tests (LFTs), renal function, CBC.
- **During Treatment**:
- **Bilirubin levels**: Periodically to assess efficacy in Gilbert Syndrome.
- **LFTs**: Periodically for signs of liver injury.
- **Clinical Signs**: Monitor for sedation, ataxia, mood changes, respiratory depression.
- **Therapeutic Drug Monitoring (TDM)**: Not routinely needed for low-dose enzyme induction, but may be used in other indications.
## Clinical Pearls
- 💡 **Long Half-Life**: Phenobarbitone has a very long half-life (50-120 hours), allowing once-daily dosing and slow accumulation to steady state.
- 💡 **Enzyme Induction**: Be mindful of numerous drug interactions due to potent enzyme induction, potentially reducing efficacy of co-administered drugs.
- 💡 **Sedation**: Even at low doses, sedation can occur, especially when starting treatment or if dose is increased.
- 💡 **Withdrawal**: Abrupt discontinuation after chronic use can cause severe withdrawal symptoms, including seizures. Taper slowly.
> **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.
